Washburn Theodore James Jr.'s Form 4 filing
Agios Pharmaceuticals, Inc. (AGIO) · filed Feb 16, 2023
- Accession no.
- 0001439222-23-000026
- Filed
- Feb 16, 2023
- Trade date
- Feb 14, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $14.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Washburn Theodore James Jr.CIK 0001874199 | Officer (Principal Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 14, 2023 | Common stock | MOption exerciseAcquired | +360 | $0.00 | $0 | 3,532 | Direct | |
| Feb 14, 2023 | Common stock | FTax withholdingDisposed | −127 | $28.91 | −$3,671.57 | 3,405 | Direct | |
| Feb 14, 2023 | Common stock | SSaleDisposed | −504 | $28.59 | −$14,409.36 | 2,901 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 14, 2023 | Common stock | MOption exerciseDisposed | −360 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.